Skip to content
ES
MARKETS / NASDAQ / EYPT
NASDAQ · LABORATORY ANALYTICAL INSTRUMENTS · SMALL CAP

EyePoint, Inc. EYPT

17 fiscal years on record · USD · FY2025 reported · SEC filings only
$31.4M
▼ 27.5% YoY
$-232.0M
$-243.4M
In brief

What this company does

The Company's pipeline leverages its proprietary bioerodible Durasert E™ technology (Durasert E™) for sustained intraocular drug delivery. EyePoint is headquartered in Watertown, Massachusetts with a commercial manufacturing facility in Northbridge, Massachusetts. We were incorporated under the laws of the state of Delaware on March 19, 2008, under the name New pSivida, Inc. We subsequently changed our name to pSivida Corp. in May 2008,to EyePoint Pharmaceuticals, Inc. in March 2018 and EyePoint, Inc. in December 2025. Our principal executive office is located at 480 Pleasant Street, Suite C400, Watertown, Massachusetts 02472, and our telephone number is (617) 926-5000.

Written from the business description in EyePoint, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 5 March 2026. Every sentence was checked against that document before publication.

Growth
USD 31.4M
Revenue, FY2025 · full 17-year series below
Revenue $M Net income $M
FY2025 · Revenue 31.4 · Net income -232.0
20M40M-80M-160M200920112013201520172019202120232025
Compound annual growth
−8.8%
−1.8%
+34.5%
+13.1%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −1.8% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−739 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -776.0% · Net -739.4%
-500%-1000%-1500%200920112013201520172019202120232025
ROE
FY2025 · ROE -72.2%
-200%-400%200920112013201520172019202120232025
Gross margin—
Operating margin-776.0%
Net margin-739.4%
Return on assets-59.3%
EBITDAUSD -241.1M

Each USD of equity lost 72 cents this year.

Cash & shareholders
—
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -243.4
-100M-200M200920112013201520172019202120232025
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—

Total assetsUSD 364.0M
EquityUSD 306.1M
CashUSD 101.8M
Current ratio8.88×

Equity funds 84% of total assets.

The 17-year record
17 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 20252024202320222021202020192018201720162015201420132012201120102009
Revenue $B0.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.00.0
Operating income $B−0.2−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.00.0
EBITDA $B−0.2−0.1−0.1−0.1−0.1−0.0−0.0·−0.0−0.0−0.00.0−0.0−0.0−0.0−0.00.0
Income tax $B0.00.00.00.00.00.00.0·0.00.0−0.00.0−0.0−0.0−0.0−0.00.0
Net income $B−0.2−0.1−0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.0−0.00.0−0.0−0.0−0.0−0.00.0
Free cash flow $B−0.2−0.1−0.0−0.1−0.1−0.0−0.1·−0.0−0.0−0.00.0−0.0−0.0−0.0−0.00.0
EPS, diluted $−3.17−2.32−1.82−2.74−2.03−3.54−5.44−1.27−1.15−0.52−0.680.21−0.49−0.52−1.19−0.440.46
Dividend / sh $·················
Payout %·················
ROE %−72.2−43.4−39.0−72.8−57.6−337.9−247.1−349.2−425.0−108.0−97.433.2−118.1−111.5−97.3−24.526.5
Shares out B0.080.070.050.030.030.020.010.100.070.040.030.030.030.020.020.02·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 66 reconciliationsAUDITED

Reconciled in 17 of 19 fiscal years. 10 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityLaboratory Analytical Instruments
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2009

Share this section

Download image